GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » NonCurrent Deferred Liabilities

Immunovia AB (LTS:0G8X) NonCurrent Deferred Liabilities : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Immunovia AB NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Immunovia AB's non-current deferred liabilities for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Immunovia AB NonCurrent Deferred Liabilities Historical Data

The historical data trend for Immunovia AB's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB NonCurrent Deferred Liabilities Chart

Immunovia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunovia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunovia AB NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Immunovia AB's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovia AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines